FDA Inspection 1231413 — AbbVie Inc.
The FDA completed an inspection of AbbVie Inc. on April 19, 2024 in North Chicago, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 19, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- North Chicago, IL (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)